clobazam / Generic mfg. - LARVOL DELTA

Pharmacokinetic variability and complex two-way interactions with cenobamate in patients with refractory epilepsy. (PubMed, Epilepsia) - "We demonstrate complex and unpredictable two-way interactions in polytherapy with CNB and pronounced pharmacokinetic variability among patients with refractory epilepsy, elucidating the usefulness of TDM."

Journal • PK/PD data • CNS Disorders • Epilepsy

Characterizing SCN1A -Related Disorders Using Real-World Data Across 681 Patient-Years. (PubMed, medRxiv) - "Changes in treatment coincided with the diagnosis of an SCN1A -related disorder, with an increase in cannabidiol, clobazam, and fenfluramine and reduction in sodium channel-blocker use following genetic diagnosis. In summary, we reconstructed the longitudinal disease history of SCN1A -related disorders from electronic medical records using a standardized framework for the analysis of real-world clinical data. We refine existing natural history data of SCN1A -related disorders by providing a granular landscape of seizures, comorbidities, and treatment approaches over time."

Journal • Real-world evidence • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

Pembrolizumab-induced Multifocal, Musicogenic, Autoimmune Epilepsy due to GAD65 Autoantibodies in a Patient Treated for Triple Negative Breast Cancer (AAN 2026) - "Design/ The patient was a 34-year-old, right-handed female with a past medical history of type 1 diabetes mellitus, hypogammaglobulinemia, systemic lupus erythematosus and triple-negative breast cancer due to the BRAC1 mutation who underwent a clinical trial with a neoadjuvant regimen of pembrolizumab plus carboplatin and docetaxel...She was maintained on intravenous immunoglobulin, hydroxychloroquine and mycophenolic acid for immunotherapy and clobazam, lamotrigine, levetiracetam, lorazepam and cenobamate for antiseizure medications. This case report describes a phenotypic evolution of GAD65 disease from adult-onset, type 1 diabetes mellitus to multifocal, musicogenic, drug-resistant autoimmune epilepsy after pembrolizumab use."

Clinical • IO biomarker • Breast Cancer • CNS Disorders • Diabetes • Epilepsy • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Oncology • Solid Tumor • Systemic Lupus Erythematosus • Triple Negative Breast Cancer • Type 1 Diabetes Mellitus

Management of febrile seizures in Türkiye: A nationwide survey of pediatricians and pediatric neurologists. (PubMed, Brain Dev) - "FS management differs between pediatricians and pediatric neurologists in Türkiye, particularly for complex cases. Pediatric neurologists favor guideline-consistent intermittent benzodiazepine-based strategies, whereas pediatricians more often prescribe continuous ASMs. Clearer guidance and improved caregiver education are needed to support evidence-based practice."

Journal • CNS Disorders • Epilepsy • Pediatrics

SAFETY AND TOLERABILITY OF A CANNABIS-BASED OIL EXTRACT IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION – A PHASE I STUDY (EBMT 2026) - "Objective: to assess the safety of a cannabis-based oil in patients undergoing aHSCT with high-dose melphalan (HDM) for multiple myeloma and plasma cell dyscrasias...Patients with prior severe psychiatric disorders or using clobazam or valproate were considered ineligible... Most patients either complained of nausea or discontinued therapy shortly after HDM. This transplant period is characterized by a high incidence of dysgeusia, chemotherapy-induced nausea and vomiting and oral mucositis, which may have contributed to poor tolerability of the oil-based CBD formulation. Difficulties in maintaining patients on-protocol, together with budgetary constraints, led investigators to terminate the study early."

Clinical • P1 data • Bipolar Disorder • Bone Marrow Transplantation • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Depression • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Mental Retardation • Mood Disorders • Mucositis • Multiple Myeloma • Neutropenia • Stomatitis • Transplantation

Seizure Clusters: Current Concepts in Definition and Treatment. (PubMed, J Clin Med) - "Consequently, the off-label use of oral benzodiazepines, including clobazam, clonazepam, and lorazepam, remains common when oral therapy is feasible, despite limited evidence. These include prompt intravenous benzodiazepine administration, followed by the intravenous loading of antiseizure medications such as brivaracetam or lacosamide in cases of seizure recurrence. In ED settings, "empirical" definitions of SCs (i.e., more than three seizures within 24 h) may facilitate timely intervention."

Journal • Review • CNS Disorders • Epilepsy

SAFETY AND TOLERABILITY OF A CANNABIS-BASED OIL EXTRACT IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION – A PHASE I STUDY (EBMT 2026) - "Objective: to assess the safety of a cannabis-based oil in patients undergoing aHSCT with high-dose melphalan (HDM) for multiple myeloma and plasma cell dyscrasias...Patients with prior severe psychiatric disorders or using clobazam or valproate were considered ineligible... Most patients either complained of nausea or discontinued therapy shortly after HDM. This transplant period is characterized by a high incidence of dysgeusia, chemotherapy-induced nausea and vomiting and oral mucositis, which may have contributed to poor tolerability of the oil-based CBD formulation. Difficulties in maintaining patients on-protocol, together with budgetary constraints, led investigators to terminate the study early."

Clinical • P1 data • Bipolar Disorder • Bone Marrow Transplantation • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Depression • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Mental Retardation • Mood Disorders • Mucositis • Multiple Myeloma • Neutropenia • Stomatitis • Transplantation

Quantitative EEG Fingerprints of Landau-Kleffner Syndrome (AAN 2026) - "Awake EEG demonstrated isolated generalized epileptiform discharges, while sleep EEG revealed >90% high-amplitude generalized spike-and-wave activity consistent with ESES...Clobazam was initiated and titrated over six months, with serial EEG monitoring showing >99% resolution of ESES over a year... Quantitative EEG showed an instantly recognizable pattern correlating with ESES pattern on scalp EEG. Quantitative EEG can serve as an effective adjunctive tool when interpreted alongside a scalp EEG in LKS."

CNS Disorders • Epilepsy • Rare Diseases • Sleep Disorder

Breaking the Cycle: GAD65 Autoimmune Epilepsy with Multidien Seizure Pattern in a Woman Misdiagnosed with Catamenial Seizures (AAN 2026) - "With the combination of rituximab, clobazam, and cenobamate, she achieved over 12 months free of bilateral tonic-clonic seizures, a significant decrease in focal seizures, and improved quality of life. Cyclical seizures in women with epilepsy should not always be presumed to be catamenial as this may incorrectly lead to harmful interventions. A multimodal approach to treatment of GAD65 TLE can result in improvement in seizures and quality of life."

Clinical • CNS Disorders • Epilepsy • Gynecology • Immunology

Polysubstance overdose with cenobamate, levetiracetam and clobazam: Insights into cenobamate toxicity. (PubMed, Seizure) - No abstract available

Journal • Anesthesia • CNS Disorders • Epilepsy

Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications (AAN 2026) - "Objective: To retrospectively examine all-cause mortality in patients after initiating cenobamate vs mortality in patients treated with selected antiseizure medications (ASMs) that have similar patterns of use in medication-resistant epilepsy.Background: A previous post-hoc analysis of survival in a clinical trial cohort showed that the all-cause standardized mortality ratio (SMR) for cenobamate-treated patients was 1.32 (95% CI: 0.84-2.0), which was not significantly different from the general population.Design/ De-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated therapeutic doses of cenobamate or another selected ASM (brivaracetam, clobazam, lacosamide, eslicarbazepine, or perampanel) between 1/1/2020-12/5/2024. Patients treated with cenobamate at therapeutic doses had lower mortality rates than patients treated with selected comparable ASM."

CNS Disorders • Epilepsy

Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate (AAN 2026) - "Objective: To evaluate the comparative effect of initiating cenobamate vs selected antiseizure medications (ASMs, brivaracetam, clobazam, eslicarbazepine, lacosamide, or perampanel) on epilepsy-related and all-cause inpatient (IP) and emergency room (ER) utilization rates.Background: Cenobamate is an ASM approved for adults in the US that has demonstrated efficacy across focal seizure subtypes.Design/ A retrospective observational study using de-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated cenobamate or another selected ASM between 1/1/202012/52024. Initiating cenobamate was associated with a significant reduction in both epilepsy-related and all-cause IP admissions and ER visits compared to propensity-matched patients who similarly could have initiated cenobamate but instead initiated other ASMs."

HEOR • CNS Disorders • Epilepsy

Refractory Autoimmune Encephalitis with Focal Status Epilepticus in a Patient with KLHL11 Antibody Syndrome (AAN 2026) - " The patient was found to have electroclinical seizures with focal status epilepticus despite extensive anti-seizure medication (ASM) therapy, including brivaracetam, lacosamide, valproic acid, phenobarbital, cenobamate, perampanel, and clobazam. This case illustrates the recurrent and refractory nature of KLHL11 antibody-associated autoimmune encephalitis, particularly when complicated by drug-resistant epilepsy. Early recognition of recurrence and escalation of immunotherapy, including rituximab, may be necessary in managing such cases. Comprehensive neurologic, immunologic, and oncologic evaluations are essential to guide ongoing therapy and improve clinical outcomes."

Clinical • CNS Disorders • Epilepsy • Germ Cell Tumors • Immunology

An Assessment of Acute Pharmacodynamic Drug-drug Interactions (PD-DDIs) Between Cannabidiol (CBD) and Cenobamate (CNB) in a Mouse Model of Generalized Tonic Seizures (AAN 2026) - "Objective: To evaluate PD-DDIs between plant-derived highly purified CBD (Epidiolex®, active pharmaceutical ingredient) and CNB in a mouse maximal electroshock seizure (MES) model.Background: Synergistic antiseizure PD-DDIs between CBD and antiseizure medications (ASMs) like clobazam have been observed in mouse seizure models. The study reveals evidence for pharmacodynamic synergism between CBD and CNB."

PK/PD data • Preclinical • CNS Disorders • Epilepsy

Touch-Screen Automatisms With Stereotyped Postictal Texting Behavior In A Case Of Drug And Surgical Refractory Epilepsy (AAN 2026) - "Status post right anterior temporal lobectomy, she is now having only nocturnal seizures originating from the left temporal lobe while also on Cenobamate, Lacosamide, and Clobazam; Engel Classification IID.Design/ N/A N/A This case highlights a unique post-ictal behavior of repetitively texting the same contacts for the patient's home address. This case highlights a unique post-ictal behavior of repetitively texting the same contacts for the patient's home address. This behavior appears to be a reliable marker of the patient's ongoing focal seizures and may serve as a useful biomarker to track her response to treatment. A literature review demonstrates that texting behavior has never been reported in relation to ictal or post-ictal processes."

Clinical • CNS Disorders • Epilepsy

Prevalence, Treatment Patterns, and Healthcare Resource Utilization Among Patients with CDKL5 Deficiency Disorder: Retrospective Analysis of US Claims Data (AAN 2026) - "Levetiracetam (34%), clobazam (33%), and clonazepam (30%) were the most common seizure-related drugs utilized. Increase in uptake post diagnosis was seen for ganaxolone (23%), fenfluramine (5%), and cenobamate (4%)... This real-world retrospective analysis reports prevalence for patients with CDD for the first time in a large, claims-based population. Comorbidities and HCRU burden are significant for patients with CDD."

HEOR • Retrospective data • Cerebral Palsy • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Movement Disorders • CDKL5

Brain with FIRES: A Pediatric Case of Therapeutic Synergism of Anakinra and IVIG (AAN 2026) - "Seizures were refractory to multiple antiseizure agents, high-dose methylprednisolone, ketamine, and pentobarbital coma. Plasmapheresis, pyridoxine challenge, propofol, intrathecal dexamethasone, and ketogenic diet for suspected FIRES were unsuccessful...His discharge regimen following 2 months of hospitalization included clobazam, perampanel, Anakinra, and IVIG... This case highlights a favorable response to combined immunotherapy in FIRES. Seizure recurrence during anakinra taper underscores its pivotal role, while improvement post-IVIG suggests synergistic benefit, emphasizing the need for further research into FIRES immunopathogenesis and combination strategies."

Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Rare Diseases • IL2

Refractory Status Epilepticus in an Infant with Succinic Semialdehyde Dehydrogenase Deficiency: A Case Report and Therapeutic Challenges (AAN 2026) - "Despite treatment with lorazepam, levetiracetam, fosphenytoin, and phenobarbital, seizures persisted, evolving into refractory status epilepticus. Ketamine infusion was started and escalated to 100 mcg/kg/min without resolution...Both anesthetic infusions were weaned over 20 days, during which levetiracetam, topiramate, clobazam, perampanel, and phenobarbital were uptitrated... Epilepsy is a recognized feature of SSADHD, though its pathophysiology and optimal management remain poorly defined. Seizure type, frequency, and treatment response are highly variable, making therapy challenging. Status epilepticus in this setting presents unique therapeutic challenges, as many conventional antiseizure agents may exacerbate GABAergic imbalance; thus, management must balance seizure control while avoiding agents that impair GABA metabolism."

Case report • Clinical • Absence Seizure Disorder • Attention Deficit Hyperactivity Disorder • CNS Disorders • Epilepsy • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Strabismus

A RETROSPECTIVE CROSS-SECTIONAL STUDY OF DRUG UTILIZATION EVALUATION OF ANTI-EPILEPTIC AGENTS IN A TERTIARY CARE HOSPITAL (ISPOR 2026) - "Except for gabapentin and pregabalin, most AEDs were prescribed as monotherapy. This study highlights prescribing trends and seizure patterns among epileptic patients in a tertiary care setting. Partial seizures were more prevalent, and a family history of epilepsy emerged as a significant risk factor. Levetiracetam, phenytoin, sodium valproate, clobazam, and midazolam were the most commonly utilized AEDs."

Observational data • Retrospective data • CNS Disorders • Epilepsy

Neurological Complications of Measles: A Case of Encephalitis in an Immunocompromised Young Adult with Seizures and Multifocal T2 Hyperintensities (AAN 2026) - "Anti-seizure medication escalated with levetiracetam, clobazam, oxcarbazepine, and valproate for better control. Measles is a highly contagious viral illness that can result in severe CNS complications, including acute postinfectious measles encephalitis (APME), measles inclusion body encephalitis (MIBE), and subacute sclerosing panencephalitis (SSPE). Although neurological sequelae are rare, they are associated with high morbidity and mortality, particularly in immunocompromised individuals and children. Recognition of CNS manifestations is critical, given the resurgence of measles globally and its devastating outcomes."

Clinical • Cardiovascular • CNS Disorders • Epilepsy • Infectious Disease • Measles

SCN9A mutations may contribute to medically refractory epilepsy (AAN 2026) - "His seizures were refractory to brivaracetam, lacosamide, zonisamide, oxcarbazepine. He is currently on clobazam, felbamate and valproic acid, with seizures occurring every other week...He is currently on zonisamide, levetiracetam, rufinamide, cannabidiol, and clobazam and continues to have seizures every few days... These cases demonstrate SCN9A gene mutations in patients with refractory epilepsy, suggesting a possible link. These specific gene mutations have not been well characterized in literature; thus, these cases may provide insight into mutations that may be pathogenic. Further research is necessary to determine exactly what role these variants play in epilepsy."

CNS Disorders • Epilepsy • NAV1 • SCN8A

Immune Checkpoint Inhibitor Induced Parkinsonism and Breakthrough Seizures in Medically Refractory Epilepsy: A Case Report (AAN 2026) - "Previously, multiple alternative antiseizure medications including Carbamazepine, Gabapentin, Ethosuximide, Zonisamide, and Levetiracetam were ineffective or poorly tolerated.The patient had received two cycles of Cemiplimab (March–April 2025) for SCC, after which his tremors and rigidity progressively worsened. This case underscores that seizures and subacute parkinsonism are rare, but significant ICI related complications. Symptom stabilization was achieved with a combination of Lacosamide, Lamotrigine, Clobazam, and Corticosteroids after other antiepileptics were poorly tolerated."

Case report • Checkpoint inhibition • Clinical • CNS Disorders • Epilepsy • Immunology • Movement Disorders • Non-melanoma Skin Cancer • Oncology • Parkinson's Disease • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Novel GTPBP2 Mutation-associated Jaberi Elahi Syndrome – A Rare Cause of Syndromic Epilepsy (AAN 2026) - "This case describes a novel gene variant associated with JABELS, and adds to the limited fund of knowledge on the clinical presentation and genetic causes of this extremely rare disorder."

CNS Disorders • Developmental Disorders • Dystonia • Epilepsy • Movement Disorders • Rare Diseases

Focal Status Epilepticus Masquerading as Stroke in Diabetic Ketoacidosis: A Diagnostic Challenge (AAN 2026) - "Seizures persisted despite levetiracetam and lacosamide treatment, meeting criteria for new-onset refractory status epilepticus (NORSE). Intubation, continuous anesthetic infusions, and ultimately triple antiseizure therapy (including clobazam) were required for seizure control by day 4... FSE can serve as a primary neurological manifestation of DKA and may closely mimic acute stroke. In cases of focal deficits without corresponding imaging abnormalities in diabetic patients, early EEG evaluation is crucial for accurate diagnosis. Recognizing this unusual presentation can prevent diagnostic delays and guide appropriate management—combining aggressive seizure control with metabolic correction."

Cardiovascular • CNS Disorders • Diabetes • Epilepsy • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

Psychogenic Non-epileptic Seizures Secondary to Forced Normalization Phenomenon in a Patient with Eyelid Myoclonia with Absence Epilepsy (Jeavons Syndrome): A Case Report (AAN 2026) - "Psychosis is most common, but other manifestations, including PNES, may occur.Design/ A 26-year-old female with long-standing, drug-resistant EEM began experiencing eyelid myoclonia and absence seizures at age 10, refractory to multiple antiseizure medications (oxcarbazepine, valproate, lamotrigine, lacosamide)...Ethosuximide was discontinued, while levetiracetam and clobazam were maintained... This is the first reported case of PNES as a manifestation of FN in EEM, representing the close interaction between epilepsy control and emergent psychiatric symptoms. Ethosuximide may act as a pharmacological trigger in susceptible patients. Early recognition of FN is crucial for preventing misdiagnosis and optimizing interdisciplinary management strategies."

Case report • Clinical • Absence Seizure Disorder • CNS Disorders • Depression • Epilepsy • Mood Disorders